A7i Intelligence

Market intelligence on Gulf life sciences. A7i Intelligence identifies where demand forms across Saudi Arabia and the GCC and routes it into market entry and distribution.

What A7i Intelligence does

A7i Intelligence reports the regulation, capital and partnerships reshaping health across the Gulf, from Saudi Arabia's National Biotechnology Strategy and its SAR 130 billion (USD 34.6 billion) non-oil GDP target to the genome and biomanufacturing programmes building across the UAE. The editorial desk reads the signal early and routes it to the companies positioned to act on it.

From signal to execution

A7i Intelligence detects the demand and two execution arms act on it. A7i Partners runs Gulf market entry for international biotech and medtech companies, covering regulatory pathway, in-Kingdom execution and procurement. A7i Wellness Distribution moves health food and supplements into Saudi Arabia's retail, pharmacy and hospitality networks.

Leadership

Brigitta Sackl, Managing Partner. Leads commercial strategy, partner selection and international origination. Clinical training and founder experience across diagnostics, aesthetics and longevity. Based between Riyadh and Melbourne.

Salman Alzahrani, Managing Partner. Leads in-Kingdom execution, government engagement and partner operations. Saudi-born and based in the Kingdom, with direct relationships across senior government and major institutional health buyers.

Dr Nadia Mandura, Senior Medical Advisor. Thirty-five years of clinical practice across the Saudi healthcare system, former Head of Home Medical Care at King Fahd General Hospital in Jeddah.

The Wire

A live intelligence feed tracking every regulatory move, tender, partnership and capital flow across Gulf life sciences, read for what it opens up. View the archive.